Surface Oncology Inc
Surface Oncology Inc logo
SURF

Surface Oncology Inc (SURF)

$0.92172.06%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$0.9
Day's Range
$0.97
$0.92
52-Week Range
$5.98
1 month return24.1%
3 month return32.78%
1 year return83.69%
5 year return92.94%

Company Information

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
OrganizationSurface Oncology Inc
Employees67
CEODr. Robert W. Ross M.D.
IndustryHealth Technology

Analyst Recommendation

based on 5 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 5 Wall street analysts offering stock ratings for Surface Oncology Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 485.87%

Current

$0.92

Target

$5.4

Recommendation Trend

Based on 5 analyst

Current1M Ago3M Ago
Buy
5
11
11
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
57.5M
Book Value
$1.86
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.23
Wall Street Target Price
5.4

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.54
Enterprise Value
-29240739
Enterprise Value/Revenue
0.33
Enterprise Value/Ebitda
0.47

Technicals

Beta
1.71
50 Day MA
1.1
200 Day MA
1.91

Institutional Holdings

ARK Investment Management LLC

9.97%

EcoR1 Capital, LLC

6.48%

Atlas Venture Associates IX, LLC

4.87%

Vanguard Group Inc

3.81%

Citadel Advisors Llc

2.28%

Goldman Sachs Group Inc

2.09%

Discover more

Frequently Asked Questions

What is Surface Oncology Inc share price today?

Can Indians buy Surface Oncology Inc shares?

How can I buy Surface Oncology Inc shares from India?

Can Fractional shares of Surface Oncology Inc be purchased?

What are the documents required to start investing in Surface Oncology Inc stocks?

What are today’s High and Low prices of Surface Oncology Inc?

What are today’s traded volumes of Surface Oncology Inc?

What is today’s market capitalisation of Surface Oncology Inc?

What is the 52 Week High and Low Range of Surface Oncology Inc?

How much percentage Surface Oncology Inc is down from its 52 Week High?

How much percentage Surface Oncology Inc is up from its 52 Week low?

What are the historical returns of Surface Oncology Inc?

Who is the Chief Executive Officer (CEO) of Surface Oncology Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*